Amedeo Smart

Free Medical Literature Service

 

Amedeo

Liver Diseases
  Free Subscription

Articles published in
Gut
    October 2025
  1. ZHANG M, Chen C, Zhang H, Long T, et al
    SIRT6 promotes intrahepatic cholangiocarcinoma development by reprogramming glutamine metabolism via enhanced GLUL.
    Gut. 2025 Oct 23:gutjnl-2025-335729. doi: 10.1136/gutjnl-2025-335729.
    >> Share

  2. YANG Z, Hu Y, Yang C, Li Y, et al
    SMYD2-mediated methylation of STAT1 protects against hepatic ischaemia/reperfusion injury by blocking JAK-STAT1 signalling pathways.
    Gut. 2025 Oct 17:gutjnl-2025-336400. doi: 10.1136/gutjnl-2025-336400.
    >> Share

  3. GAO C, Wang Y, Zhou G, Shi P, et al
    KIF1Bbeta suppresses hepatocellular carcinoma by transporting and secreting FBLN5 to attenuate the integrin pathway.
    Gut. 2025 Oct 13:gutjnl-2025-336230. doi: 10.1136/gutjnl-2025-336230.
    >> Share

  4. VANDERSCHUEREN E, Praktiknjo M, Wiest R, Cardenas A, et al
    Recent advances in clinical practice endohepatology: the endoscopic liver rush.
    Gut. 2025;74:1916-1930.
    >> Share

  5. LIU Y, Wang T, Zhang F, Liu X, et al
    Crosstalk between liver sinusoidal endothelial cells and hepatocytes via IL-1alpha-IL1R1 axis exacerbates ischaemia/reperfusion injury in aged livers.
    Gut. 2025 Oct 8:gutjnl-2025-335964. doi: 10.1136/gutjnl-2025-335964.
    >> Share

  6. XU W, Zhao Y, Weng J, Yu M, et al
    Galectin-4 drives anti-PD-L1/BVZ resistance by regulating metabolic adaptation and tumour-associated neutrophils in hepatocellular carcinoma.
    Gut. 2025 Oct 7:gutjnl-2025-336374. doi: 10.1136/gutjnl-2025-336374.
    >> Share

    September 2025
  7. SHEN Y, Jin X, Song W, Fang T, et al
    Hypothesis-generating evaluation of multi-armoured oncolytic HSV-1 (VG161) in intrahepatic cholangiocarcinoma: pooled insights from multicentre studies.
    Gut. 2025 Sep 29:gutjnl-2025-335904. doi: 10.1136/gutjnl-2025-335904.
    >> Share

  8. BUELONI B, G Fernandez-Barrena M, Fiore E, Avila MA, et al
    Epigenetic therapies in hepatocellular carcinoma: emerging clinical tools and applications.
    Gut. 2025 Sep 23:gutjnl-2025-336317. doi: 10.1136/gutjnl-2025-336317.
    >> Share

  9. CARLESSI R, Kendall TJ, Olynyk JK, Dwyer BJ, et al
    Disease-associated hepatocytes are predictive of outcomes and survival in MASLD beyond fibrosis staging.
    Gut. 2025 Sep 10:gutjnl-2025-336627. doi: 10.1136/gutjnl-2025-336627.
    >> Share

  10. FENG G, Wong VW, Targher G, Byrne CD, et al
    Non-invasive tests of fibrosis in the management of MASLD: revolutionising diagnosis, progression and regression monitoring.
    Gut. 2025;74:1741-1750.
    >> Share

  11. BU L, Zhang Y, Su Y, Wu X, et al
    High-protein diets alleviate tumour growth and drug resistance by promoting AKT aggregation and turnover.
    Gut. 2025;74:1711-1727.
    >> Share

  12. MA L, Hung MH, Rashidi Mehrabadi F, Wang L, et al
    Beneficial infections of the enterovirus genus in patients with liver cancer.
    Gut. 2025;74:1667-1679.
    >> Share

  13. CHAN M, Zhu S, Nukaya M, Ferreira LT, et al
    DNAJ-PKAc fusion heightens PLK1 inhibitor sensitivity in fibrolamellar carcinoma.
    Gut. 2025;74:1680-1693.
    >> Share

    August 2025
  14. MILARDI G, Franceschini B, Camisaschi C, Puccio S, et al
    Immunosuppressive contribution of tumour-infiltrating B cells in human intrahepatic cholangiocarcinoma and their role in chemoimmunotherapy outcome.
    Gut. 2025 Aug 31:gutjnl-2025-334861. doi: 10.1136/gutjnl-2025-334861.
    >> Share

  15. YUAN Y, Li J, Rao D, Lu X, et al
    ISG15 deficiency in hepatic stellate cells promotes TGFbeta2-induced liver fibrosis by counteracting CREB1 ISGylation.
    Gut. 2025 Aug 17:gutjnl-2025-335327. doi: 10.1136/gutjnl-2025-335327.
    >> Share

  16. LUCAS-RUIZ F, Vidal-Correoso D, Mateo SV, de la Torre-Alamo MM, et al
    Intrahepatic donor microbiota-based metataxonomic signature detected in organ preservation solution enables prediction of short-term liver transplant outcomes.
    Gut. 2025 Aug 12:gutjnl-2025-335986. doi: 10.1136/gutjnl-2025-335986.
    >> Share

  17. WU X, Quan D, Li W, Wisskirchen K, et al
    Clinical results of an HBV-specific T-cell receptor-T-cell therapy (SCG101) in patients with HBV-related hepatocellular carcinoma treated in an investigator-initiated, interventional trial.
    Gut. 2025 Aug 12:gutjnl-2025-335456. doi: 10.1136/gutjnl-2025-335456.
    >> Share

  18. FONTANELLAS A, Berraondo P, Urigo F, Jerico D, et al
    RNA-based therapies in liver metabolic diseases.
    Gut. 2025;74:1514-1527.
    >> Share


  19. Correction: Gene score to quantify systemic inflammation in patients with acutely decompensated cirrhosis.
    Gut. 2025;74:e18.
    >> Share

    July 2025
  20. PRAWIRA A, Xu H, Mei Y, Nasir NJM, et al
    Targeting Treg-fibroblast interaction to enhance immunotherapy in steatotic liver disease-related hepatocellular carcinoma.
    Gut. 2025 Jul 22:gutjnl-2025-335084. doi: 10.1136/gutjnl-2025-335084.
    >> Share

  21. GUILLOT A, Pose E
    Hepatocyte senescence in alcohol-associated hepatitis: epiphenomenon or disease-driving mechanism?
    Gut. 2025 Jul 17:gutjnl-2025-335271. doi: 10.1136/gutjnl-2025-335271.
    >> Share

    June 2025
  22. NIU J, Gao Y, Wang G, Qin Z, et al
    Rice-derived recombinant human serum albumin as an alternative to human plasma for patients with decompensated liver cirrhosis: a randomised, double-blind, positive-controlled and non-inferiority trial.
    Gut. 2025 Jun 24:gutjnl-2025-335577. doi: 10.1136/gutjnl-2025-335577.
    >> Share

  23. LAI JC, Yang B, Lee HW, Lin H, et al
    Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease.
    Gut. 2025 Jun 20:gutjnl-2025-334981. doi: 10.1136/gutjnl-2025-334981.
    >> Share

  24. CHEN J, Xu X, Yang S, Yu X, et al
    Validation of the CLIF-SIG score in patients with HBV-related acutely decompensated cirrhosis.
    Gut. 2025 Jun 19:gutjnl-2025-335810. doi: 10.1136/gutjnl-2025-335810.
    >> Share

  25. GOUGELET A
    NLRP6 deficiency enhances macrophage-mediated phagocytosis via E-Syt1 to inhibit hepatocellular carcinoma progression.
    Gut. 2025 Jun 15:gutjnl-2025-335795. doi: 10.1136/gutjnl-2025-335795.
    >> Share

  26. DE MARTIN E, Fulgenzi CAM, Celsa C, Laurent-Bellue A, et al
    Immune checkpoint inhibitors and the liver: balancing therapeutic benefit and adverse events.
    Gut. 2025;74:1165-1177.
    >> Share

  27. LI S, Fu Y, Jia X, Liu Z, et al
    NLRP6 deficiency enhances macrophage-mediated phagocytosis via E-Syt1 to inhibit hepatocellular carcinoma progression.
    Gut. 2025 Jun 5:gutjnl-2024-334448. doi: 10.1136/gutjnl-2024-334448.
    >> Share

  28. XING X, Wang SD, Yang JL, Wang Z, et al
    Presinusoidal portal hypertension with cutaneous vascular malformations.
    Gut. 2025 Jun 2:gutjnl-2025-335640. doi: 10.1136/gutjnl-2025-335640.
    >> Share

    May 2025
  29. ROSNER T, Rupp C, Lechler C, Bauer U, et al
    Activation of RAS/MEK/ERK signalling drives biliary differentiation in primary liver cancer.
    Gut. 2025 May 12:gutjnl-2024-333238. doi: 10.1136/gutjnl-2024-333238.
    >> Share

  30. WANG C, Felli E, Fallowfield JA, Dietrich CF, et al
    Vasomics of the liver.
    Gut. 2025;74:1008-1020.
    >> Share

    April 2025
  31. PINTER M, Fulgenzi CAM, Pinato DJ, Scheiner B, et al
    Systemic treatment in patients with hepatocellular carcinoma and advanced liver dysfunction.
    Gut. 2025 Apr 29:gutjnl-2025-334928. doi: 10.1136/gutjnl-2025-334928.
    >> Share

  32. MACCIONI L, Guan Y, Kim M, Parra MA, et al
    Opposite regulation of intestinal and intrahepatic CD8(+) T cells controls alcohol-associated liver disease progression.
    Gut. 2025 Apr 8:gutjnl-2024-334412. doi: 10.1136/gutjnl-2024-334412.
    >> Share

  33. CELSA C, Pennisi G, Tulone A, Ciancimino G, et al
    Glucagon-like peptide-1 receptor agonist use is associated with a lower risk of major adverse liver-related outcomes: a meta-analysis of observational cohort studies.
    Gut. 2025;74:815-824.
    >> Share

  34. JIA Q, Sun X, Li H, Guo J, et al
    Perturbation of mRNA splicing in liver cancer: insights, opportunities and challenges.
    Gut. 2025;74:840-852.
    >> Share

    March 2025
  35. XU H, Wu Z, Qin J, Li X, et al
    Stressed hepatocyte sustains alcohol-associated hepatitis progression by producing leukocyte cell-derived chemotaxin 2.
    Gut. 2025 Mar 26:gutjnl-2024-334318. doi: 10.1136/gutjnl-2024-334318.
    >> Share

  36. GOYAL NP, Xanthakos S, Schwimmer JB
    Metabolic dysfunction-associated steatotic liver disease in children.
    Gut. 2025;74:669-677.
    >> Share

  37. LI G, He J, Shi J, Li X, et al
    Bioprinting functional hepatocyte organoids derived from human chemically induced pluripotent stem cells to treat liver failure.
    Gut. 2025 Mar 3:gutjnl-2024-333885. doi: 10.1136/gutjnl-2024-333885.
    >> Share

    February 2025
  38. ZHANG Z, Huang W, Hu D, Jiang J, et al
    E-twenty-six-specific sequence variant 5 (ETV5) facilitates hepatocellular carcinoma progression and metastasis through enhancing polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC)-mediated immunosuppression.
    Gut. 2025 Feb 27:gutjnl-2024-333944. doi: 10.1136/gutjnl-2024-333944.
    >> Share

  39. TREBICKA J, Aguilar F, Queiroz Farias A, Lozano JJ, et al
    Gene score to quantify systemic inflammation in patients with acutely decompensated cirrhosis.
    Gut. 2025 Feb 26:gutjnl-2024-333876. doi: 10.1136/gutjnl-2024-333876.
    >> Share

  40. MYOJIN Y, Babaei S, Trehan R, Hoffman C, et al
    Multiomics analysis of immune correlatives in hepatocellular carcinoma patients treated with tremelimumab plus durvalumab.
    Gut. 2025 Feb 18:gutjnl-2024-334026. doi: 10.1136/gutjnl-2024-334026.
    >> Share

  41. TARGHER G, Mantovani A, Byrne CD, Tilg H, et al
    Recent advances in incretin-based therapy for MASLD: from single to dual or triple incretin receptor agonists.
    Gut. 2025;74:487-497.
    >> Share

    January 2025
  42. MARAVELIA P, Yao H, Cai C, Nascimento Silva D, et al
    Unlocking novel T cell-based immunotherapy for hepatocellular carcinoma through neoantigen-driven T cell receptor isolation.
    Gut. 2025 Jan 19:gutjnl-2024-334148. doi: 10.1136/gutjnl-2024-334148.
    >> Share

  43. CORDOBA KM, Jerico D, Jiang L, Collantes M, et al
    Systemic messenger RNA replacement therapy is effective in a novel clinically relevant model of acute intermittent porphyria developed in non-human primates.
    Gut. 2025;74:270-283.
    >> Share

  44. GHOSH S, Zhao X, Alim M, Brudno M, et al
    Artificial intelligence applied to 'omics data in liver disease: towards a personalised approach for diagnosis, prognosis and treatment.
    Gut. 2025;74:295-311.
    >> Share

  45. YANG Y, Pei T, Liu C, Cao M, et al
    Glutamine metabolic competition drives immunosuppressive reprogramming of intratumour GPR109A(+) myeloid cells to promote liver cancer progression.
    Gut. 2025;74:255-269.
    >> Share

    December 2024
  46. ZHANG Y, Xie M, Wen J, Liang C, et al
    Hepatic TM6SF2 activates antitumour immunity to suppress metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma and boosts immunotherapy.
    Gut. 2024 Dec 12:gutjnl-2024-333154. doi: 10.1136/gutjnl-2024-333154.
    >> Share

  47. CHEN J, Jiang Y, Hou M, Liu C, et al
    Nuclear translocation of plasma membrane protein ADCY7 potentiates T cell-mediated antitumour immunity in HCC.
    Gut. 2024;74:128-140.
    >> Share

    November 2024
  48. MAO X, Zhang X, Kam L, Chien N, et al
    Synergistic association of sodium-glucose cotransporter-2 inhibitor and metformin on liver and non-liver complications in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease.
    Gut. 2024;73:2054-2061.
    >> Share

  49. SINGAL AG, Narasimman M, Daher D, Yekkaluri S, et al
    Effectiveness of mailed outreach and patient navigation to promote HCC screening process completion: a multicentre pragmatic randomised clinical trial.
    Gut. 2024;73:2037-2044.
    >> Share

  50. TU Y, Wu H, Zhong C, Liu Y, et al
    Pharmacological activation of STAT1-GSDME pyroptotic circuitry reinforces epigenetic immunotherapy for hepatocellular carcinoma.
    Gut. 2024 Nov 1:gutjnl-2024-332281. doi: 10.1136/gutjnl-2024-332281.
    >> Share

    October 2024
  51. VAN DER MERWE SW, G Fernandez-Barrena M
    Safe and successful gut-restricted adsorbent strategy against cirrhosis and acute-on-chronic liver failure.
    Gut. 2024 Oct 26:gutjnl-2024-332457. doi: 10.1136/gutjnl-2024-332457.
    >> Share

  52. LINK F, Li Y, Zhao J, Munker S, et al
    ECM1 attenuates hepatic fibrosis by interfering with mediators of latent TGF-beta1 activation.
    Gut. 2024 Oct 24:gutjnl-2024-333213. doi: 10.1136/gutjnl-2024-333213.
    >> Share

  53. SALIE H, Wischer L, D'Alessio A, Godbole I, et al
    Spatial single-cell profiling and neighbourhood analysis reveal the determinants of immune architecture connected to checkpoint inhibitor therapy outcome in hepatocellular carcinoma.
    Gut. 2024 Oct 14:gutjnl-2024-332837. doi: 10.1136/gutjnl-2024-332837.
    >> Share

  54. PAN DZ, Soulette CM, Aggarwal A, Han D, et al
    Effects of tenofovir disoproxil fumarate on intrahepatic viral burden and liver immune microenvironment in patients with chronic hepatitis B.
    Gut. 2024 Oct 8:gutjnl-2024-332526. doi: 10.1136/gutjnl-2024-332526.
    >> Share

  55. ZHOU XD, Kim SU, Yip TC, Petta S, et al
    Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease.
    Gut. 2024;73:1883-1892.
    >> Share

  56. SHANG Y, Akbari C, Dodd M, Nasr P, et al
    Cause of death by fibrosis stage in 959 patients with biopsy-proven NAFLD.
    Gut. 2024;73:e30.
    >> Share


  57. Correction: Differential inflammasome activation predisposes to acute-on-chronic liver failure in human and experimental cirrhosis with and without previous decompensation.
    Gut. 2024;73:e32.
    >> Share

    September 2024
  58. ZIPPRICH A, Hernaez R
    High-risk varices in patients with Child-Pugh-Turcotte B and C: consider band ligation with carvedilol for preventing first variceal bleeding, especially in patients with MASLD-associated cirrhosis.
    Gut. 2024 Sep 18:gutjnl-2024-333263. doi: 10.1136/gutjnl-2024-333263.
    >> Share

  59. YOU W, Hu C, Zhao M, Zhang Y, et al
    Extending inflamed-class signature to predict immune checkpoint inhibitor-based combination therapy in hepatocellular carcinoma.
    Gut. 2024 Sep 11:gutjnl-2024-333375. doi: 10.1136/gutjnl-2024-333375.
    >> Share

  60. BEA S, Ko HY, Bae JH, Cho YM, et al
    Risk of hepatic events associated with use of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists, and thiazolidinediones among patients with metabolic dysfunction-associated steatotic liver disease.
    Gut. 2024 Sep 6:gutjnl-2024-332687. doi: 10.1136/gutjnl-2024-332687.
    >> Share

    August 2024
  61. CHEN J, Xu Y, Lin Y, Wang C, et al
    Hepatomegaly and ascites in a patient with UC.
    Gut. 2024 Aug 30:gutjnl-2024-333587. doi: 10.1136/gutjnl-2024-333587.
    >> Share

  62. DUBOIS V, Lefebvre P, Staels B, Eeckhoute J, et al
    Nuclear receptors: pathophysiological mechanisms and drug targets in liver disease.
    Gut. 2024;73:1562-1569.
    >> Share

  63. MANTOVANI A, Csermely A, Bilson J, Borella N, et al
    Association between primary hypothyroidism and metabolic dysfunction-associated steatotic liver disease: an updated meta-analysis.
    Gut. 2024;73:1554-1561.
    >> Share

  64. YANG AH, Tincopa MA, Tavaglione F, Ajmera VH, et al
    Prevalence of steatotic liver disease, advanced fibrosis and cirrhosis among community-dwelling overweight and obese individuals in the USA.
    Gut. 2024 Aug 7:gutjnl-2024-332917. doi: 10.1136/gutjnl-2024-332917.
    >> Share

  65. HEINRICH B, Cubero FJ
    FTO/m6A/GPNMB axis: a novel promising target for hepatocellular carcinoma (HCC) treatment?
    Gut. 2024 Aug 1:gutjnl-2024-332934. doi: 10.1136/gutjnl-2024-332934.
    >> Share

    July 2024
  66. TEVETHIA HV, Pande A, Vijayaraghavan R, Kumar G, et al
    Combination of carvedilol with variceal band ligation in prevention of first variceal bleed in Child-Turcotte-Pugh B and C cirrhosis with high-risk oesophageal varices: the 'CAVARLY TRIAL'.
    Gut. 2024 Jul 27:gutjnl-2023-331181. doi: 10.1136/gutjnl-2023-331181.
    >> Share

  67. CAMPANI C, Imbeaud S, Couchy G, Ziol M, et al
    Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments.
    Gut. 2024 Jul 25:gutjnl-2024-331956. doi: 10.1136/gutjnl-2024-331956.
    >> Share

  68. WANG Y, Heymann F, Peiseler M
    Intravital imaging: dynamic insights into liver immunity in health and disease.
    Gut. 2024;73:1364-1375.
    >> Share

  69. LOOMBA R, Amangurbanova M, Bettencourt R, Madamba E, et al
    MASH Resolution Index: development and validation of a non-invasive score to detect histological resolution of MASH.
    Gut. 2024;73:1343-1349.
    >> Share

    June 2024
  70. HA S, Wong VW, Zhang X, Yu J, et al
    Interplay between gut microbiome, host genetic and epigenetic modifications in MASLD and MASLD-related hepatocellular carcinoma.
    Gut. 2024 Jun 29:gutjnl-2024-332398. doi: 10.1136/gutjnl-2024-332398.
    >> Share

  71. KEGGENHOFF FL, Castven D, Becker D, Stojkovic S, et al
    PARP-1 selectively impairs KRAS-driven phenotypic and molecular features in intrahepatic cholangiocarcinoma.
    Gut. 2024 Jun 10:gutjnl-2023-331237. doi: 10.1136/gutjnl-2023-331237.
    >> Share

  72. BU L, Zhang Z, Chen J, Fan Y, et al
    High-fat diet promotes liver tumorigenesis via palmitoylation and activation of AKT.
    Gut. 2024;73:1156-1168.
    >> Share

  73. NISCHALKE HD, Nischalke C, Schmalz F, Moller C, et al
    Catecholamines and inflammation in advanced liver disease: more closely intertwined than expected?
    Gut. 2024;73:1219-1222.
    >> Share

  74. CHEN A, Zhang VX, Zhang Q, Sze KM, et al
    Targeting the oncogenic m6A demethylase FTO suppresses tumourigenesis and potentiates immune response in hepatocellular carcinoma.
    Gut. 2024 Jun 5:gutjnl-2024-331903. doi: 10.1136/gutjnl-2024-331903.
    >> Share

    May 2024
  75. BABUTA M, Morel C, de Carvalho Ribeiro M, Calenda C, et al
    Neutrophil extracellular traps activate hepatic stellate cells and monocytes via NLRP3 sensing in alcohol-induced acceleration of MASH fibrosis.
    Gut. 2024 May 22:gutjnl-2023-331447. doi: 10.1136/gutjnl-2023-331447.
    >> Share

  76. WEN J, Zhang X, Wong CC, Zhang Y, et al
    Targeting squalene epoxidase restores anti-PD-1 efficacy in metabolic dysfunction-associated steatohepatitis-induced hepatocellular carcinoma.
    Gut. 2024 May 13:gutjnl-2023-331117. doi: 10.1136/gutjnl-2023-331117.
    >> Share

  77. GEIER A, Trost J, Wang K, Schmid C, et al
    PNPLA3 fatty liver allele was fixed in Neanderthals and segregates neutrally in humans.
    Gut. 2024;73:1008-1014.
    >> Share

  78. ISRAELSEN M, Alvarez-Silva C, Madsen BS, Hansen CD, et al
    Impact of acute alcohol consumption on circulating microbiome in asymptomatic alcohol-related liver disease.
    Gut. 2024;73:1041-1044.
    >> Share

  79. ROCA SUAREZ AA, Plissonnier ML, Grand X, Michelet M, et al
    TLR8 agonist selgantolimod regulates Kupffer cell differentiation status and impairs HBV entry into hepatocytes via an IL-6-dependent mechanism.
    Gut. 2024 May 2:gutjnl-2023-331396. doi: 10.1136/gutjnl-2023-331396.
    >> Share

    April 2024
  80. BREITKOPF-HEINLEIN K, Martinez-Chantar ML
    Targeting hepatic stellate cells to combat liver fibrosis: where do we stand?
    Gut. 2024 Apr 25:gutjnl-2023-331785. doi: 10.1136/gutjnl-2023-331785.
    >> Share


  81. Correction: Wnt signalling modulates transcribed-ultraconserved regions in hepatobiliary cancers.
    Gut. 2024 Apr 23:gutjnl-2016-312278corr1. doi: 10.1136/gutjnl-2016-312278.
    >> Share

  82. SUDDLE A, Reeves H, Hubner R, Marshall A, et al
    British Society of Gastroenterology guidelines for the management of hepatocellular carcinoma in adults.
    Gut. 2024 Apr 16:gutjnl-2023-331695. doi: 10.1136/gutjnl-2023-331695.
    >> Share

  83. LIU J, MacNaughtan J, Kerbert AJC, Portlock T, et al
    Clinical, experimental and pathophysiological effects of Yaq-001: a non-absorbab le, gut-restricted adsorbent in models and patients with cirrhosis.
    Gut. 2024 Apr 15:gutjnl-2023-330699. doi: 10.1136/gutjnl-2023-330699.
    >> Share

  84. SUISSA S, Hernaez R
    Glucagon-like peptide-1 receptor agonists to treat chronic liver disease: real-world evidence or ambiguity?
    Gut. 2024;73:721-724.
    >> Share

  85. LIU B, Peng G, Yin Y, Shen C, et al
    Genetic evidence for repurposing of glucagon-like peptide-1 receptor agonists to prevent chronic liver diseases.
    Gut. 2024;73:879-882.
    >> Share

  86. WESTER A, Shang Y, Toresson Grip E, Matthews AA, et al
    Glucagon-like peptide-1 receptor agonists and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes.
    Gut. 2024;73:835-843.
    >> Share

  87. ARMANDI A, Sanavia T, Younes R, Caviglia GP, et al
    Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver disease.
    Gut. 2024;73:825-834.
    >> Share

    March 2024
  88. TREBICKA J, Hernaez R, Shawcross DL, Gerbes AL, et al
    Recent advances in the prevention and treatment of decompensated cirrhosis and acute-on-chronic liver failure (ACLF) and the role of biomarkers.
    Gut. 2024 Mar 25:gutjnl-2023-330584. doi: 10.1136/gutjnl-2023-330584.
    >> Share

  89. HILDT E, Hu J
    New facet of CARs: HBV-specific CARs as inhibitors of virus morphogenesis and release.
    Gut. 2024;73:566-567.
    >> Share

  90. TARGHER G, Byrne CD, Tilg H
    MASLD: a systemic metabolic disorder with cardiovascular and malignant complications.
    Gut. 2024;73:691-702.
    >> Share

    February 2024
  91. LEE HH, Lee HA, Kim EJ, Kim HY, et al
    Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease.
    Gut. 2024;73:533-540.
    >> Share

  92. CUBERO FJ, Sarobe P, Tiegs G
    Advancing with cancer immunotherapeutics: CD29(+) regulatory T cell antagonism.
    Gut. 2024;73:391-392.
    >> Share

  93. GREEN BL, Myojin Y, Ma C, Ruf B, et al
    Immunosuppressive CD29(+) Treg accumulation in the liver in mice on checkpoint inhibitor therapy.
    Gut. 2024;73:509-520.
    >> Share

  94. HUNTER H, Johnston AJ, Said W, Wong NA, et al
    Colonic spider naevi in a middle-aged man.
    Gut. 2024;73:441-520.
    >> Share

  95. QIAN Z, Liang J, Huang R, Song W, et al
    HBV integrations reshaping genomic structures promote hepatocellular carcinoma.
    Gut. 2024 Feb 23:gutjnl-2023-330414. doi: 10.1136/gutjnl-2023-330414.
    >> Share

  96. EL-SERAG H, Kanwal F, Ning J, Powell H, et al
    Serum biomarker signature is predictive of the risk of hepatocellular cancer in patients with cirrhosis.
    Gut. 2024 Feb 16:gutjnl-2024-332034. doi: 10.1136/gutjnl-2024-332034.
    >> Share

  97. KEATING CR, Calvisi DF, Qiu W
    High-fat diet-induced AKT-palmitoylation in hepatocellular carcinoma: a breakthrough mechanistic investigation.
    Gut. 2024 Feb 9:gutjnl-2023-331857. doi: 10.1136/gutjnl-2023-331857.
    >> Share

    January 2024
  98. HE T, Zhang D
    Non-linear association of baseline viral load with on-treatment hepatocellular carcinoma risk in chronic hepatitis B: still needs further discussion.
    Gut. 2024 Jan 22:gutjnl-2023-331443. doi: 10.1136/gutjnl-2023-331443.
    >> Share

  99. BARCENA-VARELA M, Berraondo P
    Targeting metalloproteases is a promising strategy to enhance immunotherapy responses by overcoming immune exclusion in hepatocellular carcinoma.
    Gut. 2024 Jan 9:gutjnl-2023-331647. doi: 10.1136/gutjnl-2023-331647.
    >> Share


  100. Correction: P23 Opportunistic cirrhosis case finding in alcohol dependent inpatients through alcohol specialist nurse assessment and transient elastography: early detection in a high-risk group.
    Gut. 2024;73:e3.
    >> Share

  101. KONG M, Zhou J, Kang A, Kuai Y, et al
    Histone methyltransferase Suv39h1 regulates hepatic stellate cell activation and is targetable in liver fibrosis.
    Gut. 2024 Jan 4:gutjnl-2023-329671. doi: 10.1136/gutjnl-2023-329671.
    >> Share

    December 2023
  102. YANG TC, Chen WC, Hou MC, Chen PH, et al
    Endoscopic variceal ligation versus propranolol for the primary prevention of oesophageal variceal bleeding in patients with hepatocellular carcinoma: an open-label, two-centre, randomised controlled trial.
    Gut. 2023 Dec 14:gutjnl-2023-330419. doi: 10.1136/gutjnl-2023-330419.
    >> Share

  103. CAI N, Cheng K, Ma Y, Liu S, et al
    Targeting MMP9 in CTNNB1 mutant hepatocellular carcinoma restores CD8(+) T cell-mediated antitumour immunity and improves anti-PD-1 efficacy.
    Gut. 2023 Dec 13:gutjnl-2023-331342. doi: 10.1136/gutjnl-2023-331342.
    >> Share

  104. HEINEN N, Khanal R, Westhoven S, Klohn M, et al
    Productive infection of primary human hepatocytes with SARS-CoV-2 induces antiviral and proinflammatory responses.
    Gut. 2023 Dec 12:gutjnl-2023-330961. doi: 10.1136/gutjnl-2023-330961.
    >> Share

  105. YU X, Pfefferkorn M, van Bommel F, Zhang X, et al
    Clinical applications of circulating HBV RNA as a potential surrogate biomarker for intrahepatic cccDNA transcriptional activity.
    Gut. 2023 Dec 11:gutjnl-2023-331217. doi: 10.1136/gutjnl-2023-331217.
    >> Share

  106. CHOUIK Y, Levrero M
    Monocyte phenotypic liquid biopsy for NASH and liver fibrosis diagnosis: a new kid on the block.
    Gut. 2023;73:10-11.
    >> Share

    November 2023
  107. LI R, Liu X, Huang X, Zhang D, et al
    Single-cell transcriptomic analysis deciphers heterogenous cancer stem-like cells in colorectal cancer and their organ-specific metastasis.
    Gut. 2023 Nov 30:gutjnl-2023-330243. doi: 10.1136/gutjnl-2023-330243.
    >> Share

  108. ZHANG X, Yip TC, Wong GL, Leow WX, et al
    Clinical care pathway to detect advanced liver disease in patients with type 2 diabetes through automated fibrosis score calculation and electronic reminder messages: a randomised controlled trial.
    Gut. 2023;72:2364-2371.
    >> Share

  109. RODERBURG C, Kostev K, Mertens A, Luedde T, et al
    Non-alcoholic fatty liver disease (NAFLD) is associated with an increased incidence of extrahepatic cancer.
    Gut. 2023;72:2383-2384.
    >> Share

  110. EN LI CHO E, Ang CZ, Quek J, Fu CE, et al
    Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis.
    Gut. 2023;72:2138-2148.
    >> Share


  111. Correction: Sympathetic nervous activation, mitochondrial dysfunction and outcome in acutely decompensated cirrhosis: the metabolomic prognostic models (CLIF-C MET).
    Gut. 2023;72:e4.
    >> Share

    October 2023
  112. BRENNAN PN, Zelber-Sagi S, Allen AM, Dillon JF, et al
    Beyond a liver-gut focus: the evolution of gastroenterology and hepatology in challenging the obesity and steatotic liver disease paradigm.
    Gut. 2023 Oct 28:gutjnl-2023-330771. doi: 10.1136/gutjnl-2023-330771.
    >> Share

  113. ARECHEDERRA M, Casadei Gardini A, Raggi C
    More than shots in the dark: improving patient stratification to move closer to personalised therapies in intrahepatic cholangiocarcinoma.
    Gut. 2023 Oct 27:gutjnl-2023-331119. doi: 10.1136/gutjnl-2023-331119.
    >> Share

  114. JUANOLA A, Ma AT, de Wit K, Gananandan K, et al
    Novel prognostic biomarkers in decompensated cirrhosis: a systematic review and meta-analysis.
    Gut. 2023 Oct 26:gutjnl-2023-329923. doi: 10.1136/gutjnl-2023-329923.
    >> Share

  115. TESTONI B, Scholtes C, Plissonnier ML, Paturel A, et al
    Quantification of circulating HBV RNA expressed from intrahepatic cccDNA in untreated and NUC treated patients with chronic hepatitis B.
    Gut. 2023 Oct 25:gutjnl-2023-330644. doi: 10.1136/gutjnl-2023-330644.
    >> Share

  116. CHOI WM, Kim GA, Choi J, Choi GH, et al
    Non-linear association of baseline viral load with on-treatment hepatocellular carcinoma risk in chronic hepatitis B.
    Gut. 2023 Oct 9:gutjnl-2023-330225. doi: 10.1136/gutjnl-2023-330225.
    >> Share

  117. MUKHOPADHYA I
    Is HBx protein the X factor in the pathogenesis of IBD?
    Gut. 2023;72:1808-1809.
    >> Share

  118. CIOCAN D, Turpin W
    New insights into an old paradigm: why IgA accumulates in alcoholic liver disease and what could be its role.
    Gut. 2023;72:1812-1814.
    >> Share

  119. AVILA MA
    MicroRNA-223: a key regulator of liver tumour microenvironment.
    Gut. 2023;72:1811-1812.
    >> Share

    September 2023
  120. MANTOVANI A, Tilg H, Targher G
    FGF-21 analogues for treatment of non-alcoholic steatohepatitis and fibrosis: a meta-analysis with fragility index of phase 2 randomised placebo-controlled trials.
    Gut. 2023 Sep 27:gutjnl-2023-331115. doi: 10.1136/gutjnl-2023-331115.
    >> Share

  121. O'ROURKE CJ, Salati M, Rae C, Carpino G, et al
    Molecular portraits of patients with intrahepatic cholangiocarcinoma who diverge as rapid progressors or long survivors on chemotherapy.
    Gut. 2023 Sep 27:gutjnl-2023-330748. doi: 10.1136/gutjnl-2023-330748.
    >> Share

    June 2023
  122. POTENZA A, Balestrieri C, Spiga M, Albarello L, et al
    Revealing and harnessing CD39 for the treatment of colorectal cancer and liver metastases by engineered T cells.
    Gut. 2023 Jun 30:gutjnl-2022-328042. doi: 10.1136/gutjnl-2022-328042.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016